OnKure Therapeutics, Inc. (OKUR) Stock

OnKure Therapeutics, Inc. (OKUR) is a Healthcare stock trading at $3.92 (as of 2026-08-21), with a market capitalization of $158.95M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OnKure Therapeutics, Inc. focuses on the discovery and development of oncology-precision medicines, including selective histone deacetylase inhibitors. Its development portfolio includes OKI-179, which is being studied for treatment of both hematological and solid tumors.

Understand OnKure Therapeutics, Inc.: how it makes money

OnKure Therapeutics develops oncology-precision medicines using selective histone deacetylase, or HDAC, inhibitors, including OKI-179 and OKI-219, and it aims to create value by advancing these programs through clinical trials.

With revenue not shown, the profit-model engine is clinical execution, measured by patient enrollment and dosing across its oncology studies, because program advancement is what must happen before any potential product revenue.

Business quality (Weak): Promising oncology-focused targeting and measurable trial activity are present, but the company shows no reported revenue and a deeply negative operating margin, so near-term outcomes remain highly execution dependent.

Bull case

  • Trial momentum in pivotal and follow-on studies: Patients Enrolled in the Pivotal STRIDE Study is 213, and STRIDE AHEAD Enrollment Rate is 88 percent.
  • Evidence of specific drug targeting in the development platform: Pan-Mutant Development Candidate Selectivity Versus Wild Type is shown as 10.0.

Bear case

  • No reported revenue so far: Revenue is shown as 0.0 for the latest reported period, which means the business is not yet demonstrating commercial cash flow.
  • Heavy operating losses: Operating margin is -3409.4, indicating substantial ongoing costs relative to revenue.
  • Clinical progress can be uneven across programs: Patient counts vary by study and arm, for example Patients Enrolled in the STRIDE AHEAD Study is 100, and PIKture-01 trial enrollment metrics for OKI-219 arms are 38 and 33.
Valuation — source: SEC EDGAR (first-party)
Price$3.92
Market Cap$158.95M
Price / Book0.92
Price / Sales48.56
FCF Yield-30.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.44M
Net Margin-1729.6%
Revenue Growth (YoY)362.1%
EPS Growth (YoY)-0.9%
FCF Growth (YoY)34.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.63 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($16.55M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEONicholas A. Saccomano
Employees46
CountryUS
IPO Date2021-04-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Cue Biopharma, Inc. (CUE)
  • Lifecore Biomedical, Inc. (LFCR)
  • Indaptus Therapeutics, Inc. (INDP)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Assertio Holdings, Inc. (ASRT)
  • Unicycive Therapeutics, Inc. (UNCY)
  • Aardvark Therapeutics, Inc. Common Stock (AARD)
  • Equillium, Inc. (EQ)
OKUR earnings history · OKUR institutional & insider holders · OKUR KPIs & operating metrics · OKUR financials · OKUR investor presentations & press releases · OKUR SEC filings · OKUR peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.